Morgan Stanley
CALT

Morgan Stanley’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Morgan Stanley’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-919
Closed -$35.8K – 8068
2024
Q2 		$35.8K Sell
919
-5,067
-85% -$139K ﹤0.01% 6271
2024
Q1 		$126K Buy
5,986
+4,782
+397% +$106K ﹤0.01% 5898
2023
Q4 		$31K Sell
1,204
-1,124
-48% -$21K ﹤0.01% 6516
2023
Q3 		$42.5K Sell
2,328
-328
-12% -$5.67K ﹤0.01% 6235
2023
Q2 		$42.1K Buy
2,656
+1,269
+91% +$26.8K ﹤0.01% 6277
2023
Q1 		$33.2K Sell
1,387
-51
-4% -$1.02K ﹤0.01% 6438
2022
Q4 		$24.4K Buy
1,438
+305
+27% +$4.92K ﹤0.01% 6601
2022
Q3 		$18K Sell
1,133
-3,162
-74% -$55.1K ﹤0.01% 6844
2022
Q2 		$76K Buy
4,295
+3,566
+489% +$62.1K ﹤0.01% 6412
2022
Q1 		$14K Sell
729
-2,026
-74% -$40.6K ﹤0.01% 7293
2021
Q4 		$69K Buy
2,755
+750
+37% +$15.1K ﹤0.01% 6648
2021
Q3 		$43K Buy
2,005
+992
+98% +$27.2K ﹤0.01% 6792
2021
Q2 		$30K Buy
1,013
+317
+46% +$9.07K ﹤0.01% 6863
2021
Q1 		$19K Buy
+696
New +$20.8K ﹤0.01% 6739
2020
Q3 		– Sell
-69
Closed -$2K – 6858
2020
Q2 		$2K Buy
+69
New +$1.37K ﹤0.01% 6471

Other funds holding CALT

CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MTIC
Missouri Trust & Investment Company Springfield, Missouri $341M AUM 17.31% 1-Year Est. Return

Morgan Stanley's CALT Position: Q3 2024 in Review

Morgan Stanley sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2024, closing a stake of 919 shares — an estimated $35.8K sold.

Morgan Stanley first reported a position in CALT in Q2 2020 and held it in 15 quarters. The position peaked at $126K in Q1 2024. 5 funds tracked by Wall St. Rank hold CALT as of Q3 2024.

  • Morgan Stanley reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2024 after selling out during the quarter.
  • Morgan Stanley sold 919 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2024, an estimated $35.8K.
  • Morgan Stanley first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2020 and held it in 15 quarters.
  • Morgan Stanley's Calliditas Therapeutics AB American Depositary Shares position peaked at $126K in Q1 2024.
  • 5 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2024.

Based on Morgan Stanley's 13F filing for Q3 2024, filed 14 Nov 2024.